IL174765A0 - Method of treating airway diseases with beta-adrenergic inverse agonists - Google Patents

Method of treating airway diseases with beta-adrenergic inverse agonists

Info

Publication number
IL174765A0
IL174765A0 IL174765A IL17476506A IL174765A0 IL 174765 A0 IL174765 A0 IL 174765A0 IL 174765 A IL174765 A IL 174765A IL 17476506 A IL17476506 A IL 17476506A IL 174765 A0 IL174765 A0 IL 174765A0
Authority
IL
Israel
Prior art keywords
beta
inverse agonists
airway diseases
adrenergic inverse
treating airway
Prior art date
Application number
IL174765A
Other languages
English (en)
Original Assignee
Inverseon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inverseon Inc filed Critical Inverseon Inc
Publication of IL174765A0 publication Critical patent/IL174765A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL174765A 2003-10-09 2006-04-03 Method of treating airway diseases with beta-adrenergic inverse agonists IL174765A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51025003P 2003-10-09 2003-10-09
US55579704P 2004-03-23 2004-03-23
PCT/US2004/033157 WO2005034871A2 (en) 2003-10-09 2004-10-08 Methods for treating diseases and conditions with inverse agonists

Publications (1)

Publication Number Publication Date
IL174765A0 true IL174765A0 (en) 2008-04-13

Family

ID=34437322

Family Applications (1)

Application Number Title Priority Date Filing Date
IL174765A IL174765A0 (en) 2003-10-09 2006-04-03 Method of treating airway diseases with beta-adrenergic inverse agonists

Country Status (7)

Country Link
US (1) US9539221B2 (https=)
EP (2) EP1684764A2 (https=)
JP (1) JP2007527409A (https=)
AU (2) AU2004279438A1 (https=)
CA (2) CA2544733A1 (https=)
IL (1) IL174765A0 (https=)
WO (2) WO2005034871A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PT1606261E (pt) 2003-03-10 2010-01-11 Nycomed Gmbh Novo processo para a preparação de roflumilast
EP1725226A2 (en) * 2004-03-17 2006-11-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
EP1755595A1 (en) * 2004-05-10 2007-02-28 Altana Pharma AG Use of roflumilast for the prophylaxis or treatment of emphysema
US8691877B2 (en) 2004-10-15 2014-04-08 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
AU2006269944A1 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
CA2807854A1 (en) * 2009-08-12 2011-02-17 Pulmosonix Pty Ltd Determining dynamic airway response in a subject
WO2012096866A2 (en) * 2011-01-10 2012-07-19 Inverseon, Inc. Use of beta-adrenergic inverse agonists for smoking cessation
US11382513B2 (en) 2016-11-08 2022-07-12 Palo Alto Investors Methods and compositions for treating a condition in a subject
ES3040411T3 (en) 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
WO2020198466A1 (en) 2019-03-27 2020-10-01 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
EP4076422A4 (en) 2019-12-18 2024-01-24 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
WO2022192252A1 (en) * 2021-03-09 2022-09-15 Chronic Airway Therapeutics Limited Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway
WO2023250334A1 (en) * 2022-06-21 2023-12-28 Curasen Therapeutics, Inc. Compositions and methods involving isolated compounds
WO2023250332A1 (en) * 2022-06-21 2023-12-28 Curasen Therapeutics, Inc. Compositions and methods involving isolated compounds
CN116199596B (zh) * 2023-03-06 2025-03-25 梯尔希（南京）药物研发有限公司 一种特布他林代谢物的制备方法
WO2024189434A1 (en) * 2023-03-13 2024-09-19 Chronic Airway Therapeutics Limited USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36547A (en) * 1862-09-23 Improvement in locks
US4428926A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release propranolol system
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5116867A (en) * 1989-06-30 1992-05-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services D-propranolol as a selective adenosine antagonist
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5633259A (en) * 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US6593094B2 (en) * 1992-09-30 2003-07-15 Richard G. Lanzara Compositions to enhance the efficacy and safety of bio-pharmaceutical drugs
US6673558B1 (en) * 1992-09-30 2004-01-06 Richard G. Lanzara Drug compositions to prevent desensitization of cellular receptors
US5597699A (en) * 1992-09-30 1997-01-28 Lanzara; Richard G. Method for determining drug compositions to prevent desensitization of cellular receptors
US5585348A (en) * 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
JPH10251147A (ja) 1997-03-06 1998-09-22 Akira Matsumori 炎症性疾患の予防・治療剤
US6284800B1 (en) * 1997-03-13 2001-09-04 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of asthma
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US6541209B1 (en) * 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6420541B1 (en) * 1998-04-14 2002-07-16 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
CA2316273A1 (en) * 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Sustained-release composition, method of its production and use thereof
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
MXPA00010060A (es) * 1998-04-14 2004-04-23 Arena Pharm Inc Receptores de serotonina humana constitutivamente activados, no endogenos y moduladores de molecula pequenos de los mismos.
IL139254A0 (en) * 1998-06-10 2001-11-25 Arena Pharm Inc Acetylcholine enhancers
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6420563B1 (en) * 1998-07-31 2002-07-16 Arena Pharmaceuticals, Inc. Small molecule modulators of G protein-coupled receptor six
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
CN1420929A (zh) * 2000-04-07 2003-05-28 阿瑞那制药公司 非内源性组成型活化的已知g蛋白偶联受体
AU2001292897A1 (en) 2000-09-21 2002-04-02 Richard Agustin Bond Novel therapy
HUP0301377A3 (en) * 2000-10-31 2005-12-28 Boehringer Ingelheim Pharma Combination pharmaceutical composition in form of inhalative solution containing a tiotropium salt
US7018812B2 (en) * 2000-11-03 2006-03-28 Duke University Modified G-protein coupled receptors
AU2002305066B8 (en) * 2001-03-23 2008-04-17 Albert Einstein College Of Medicine Of Yeshiva University Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting GM1-ganglioside
WO2003000735A2 (en) * 2001-06-26 2003-01-03 Decode Genetics Ehf. Nucleic acids encoding olfactory receptors
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system

Also Published As

Publication number Publication date
WO2005034871A2 (en) 2005-04-21
EP1684764A2 (en) 2006-08-02
US9539221B2 (en) 2017-01-10
US20080254022A1 (en) 2008-10-16
CA2544733A1 (en) 2005-04-21
WO2005035731A3 (en) 2006-01-12
EP1677778A2 (en) 2006-07-12
AU2004280638A2 (en) 2005-04-21
WO2005035731A2 (en) 2005-04-21
AU2004279438A1 (en) 2005-04-21
CA2544611A1 (en) 2005-04-21
WO2005034871A3 (en) 2005-11-24
AU2004280638A1 (en) 2005-04-21
AU2004279438A2 (en) 2005-04-21
JP2007527409A (ja) 2007-09-27

Similar Documents

Publication Publication Date Title
IL174765A0 (en) Method of treating airway diseases with beta-adrenergic inverse agonists
ZA200508427B (en) Methods for treating interleuking-6 related diseases
IL169602A0 (en) Methods of treating lung diseases
PL1706112T3 (pl) Sposoby leczenia chorób związanych z zapaleniem
GB0308731D0 (en) Method of radiotherapy
ZA200700904B (en) Method of treating sjögren's syndrome
GB0325192D0 (en) Method of use
IL240410A0 (en) Hemolytic disease treatment method
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
IL169633A0 (en) Combination therapy for treating protein deficiencies
PL378026A1 (pl) Leczenie chorób z zastosowaniem pełnych agonistów receptora Ó-7 nACh
EP1677794A4 (en) METHODS OF TREATING DISORDERS
IL183079A0 (en) Method and fluorinated compositions for treating amyloid-related diseases
AU2003299864A8 (en) Sirna compounds and methods for the downregulation of gene expression
EP1622674A4 (en) METHOD FOR THE TREATMENT OF GLANDULAR DISORDERS AND CRoutING DISEASES
IL175351A0 (en) Methods of treating asthma
EP1701735A4 (en) METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF DIABETES
EP1581095A4 (en) THERAPEUTIC METHODS FOR REDUCING FAT DEPOSIT AND TREATING THE DISEASES THEREOF
GB0301972D0 (en) Method for identifying novel treatments
GB0422634D0 (en) Method of treating skin diseases
GB0302572D0 (en) Method of treatment
GB0306309D0 (en) Method of treatment
AU2003272247A8 (en) Methods of treating age-related defects and diseases
EP1485466A4 (en) METHOD FOR THE TREATMENT OF DISEASES OR CONDITIONS WITH PEPTIDE CONSTRUCTS
EP1648232A4 (en) ARGATROBAN TREATMENT METHOD FOR PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA